<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503113</url>
  </required_header>
  <id_info>
    <org_study_id>BA20341</org_study_id>
    <nct_id>NCT00503113</nct_id>
  </id_info>
  <brief_title>A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.</brief_title>
  <official_title>A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 3 arm study will evaluate renal safety after administration of an intravenous (iv)
      injection or infusion of Bonviva, compared to oral alendronate, in patients with
      postmenopausal osteoporosis, at increased risk of renal disease. Patients will be randomized
      to receive Bonviva 3mg intravenous (iv) by a) injection or b) infusion once every 3 months,
      or alendronate 70mg per oral (po) weekly. The anticipated time on study treatment is 3-12
      months, and the target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula)</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>The primary parameter of the study was the change (mL/min) from baseline in actual GFR (abbreviated MDRD formula using the patients' actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula)</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Change (mL/min) from baseline in actual GFR (using Cockcroft-Gault [CG] formula) after 9 months (or 40 weeks) of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula)</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Change (mL/min) from baseline in actual GFR (abbreviated MDRD formula using the patient's actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Actual GFR (Using CG Formula)</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Change (mL/min) from baseline in actual GFR (CG formula using the patient's actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Mean Serum Creatinine.</measure>
    <time_frame>Baseline and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Mean Serum Creatinine.</measure>
    <time_frame>Baseline and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Urine Albumin-to-Creatinine Ratio.</measure>
    <time_frame>Baseline and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio.</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>The relative change from baseline in this case is positively skewed (while the absolute change is not) and the means tends to more positive values.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">801</enrollment>
  <condition>Post-Menopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate [Bonviva/Boniva]</intervention_name>
    <description>3mg intravenous (iv) injection every 3 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate [Bonviva/Boniva]</intervention_name>
    <description>3mg intravenous (iv) infusion every 3 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>70mg per oral (po) weekly</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients, &gt;=60 years of age;

          -  &gt;=5 years postmenopausal;

          -  confirmed osteoporosis, at increased risk for renal disease.

        Exclusion Criteria:

          -  inability to stand or sit upright for 30 minutes;

          -  hypersensitivity to bisphosphonates;

          -  malignant disease (other than successfully resected basal cell cancer) within previous
             10 years, or breast cancer diagnosed within previous 20 years;

          -  previous administration of an i.v. bisphosphonate;

          -  oral bisphosphonate treatment other than study medication within 30 days prior to the
             baseline dosing visit and during the study;

          -  history of major upper gastrointestinal disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1012-CFed</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1117ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425 AWC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>X5000BNB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasilia</city>
        <zip>71625-009</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vitoria</city>
        <zip>29055-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <zip>44629</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obregon</city>
        <zip>85000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jerónimo Chicahualco</city>
        <zip>52170</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <zip>3630</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parow</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <zip>4055</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <results_first_submitted>March 31, 2011</results_first_submitted>
  <results_first_submitted_qc>May 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2011</results_first_posted>
  <last_update_submitted>May 17, 2011</last_update_submitted>
  <last_update_submitted_qc>May 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Disclosures Group</name_title>
    <organization>Hoffmann-La Roche</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Total 801 participants randomized. Of the randomized patients, 263 who received at least one dose of ibandronate as an injection, 263 who received at least one dose of ibandronate as an infusion and 267 patients who received at least one dose of alendronate had at least one post-baseline assessment and were included in the safety analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibandronate 3 mg Injection</title>
          <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
        </group>
        <group group_id="P2">
          <title>Ibandronate 3 mg Infusion</title>
          <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
        </group>
        <group group_id="P3">
          <title>Alendronate 70 mg Oral</title>
          <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="264"/>
                <participants group_id="P3" count="269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat Population (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="261"/>
                <participants group_id="P3" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population (PP)</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="243"/>
                <participants group_id="P3" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="263"/>
                <participants group_id="P3" count="267"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="236"/>
                <participants group_id="P3" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibandronate 3 mg Injection</title>
          <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
        </group>
        <group group_id="B2">
          <title>Ibandronate 3 mg Infusion</title>
          <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
        </group>
        <group group_id="B3">
          <title>Alendronate 70 mg Oral</title>
          <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="263"/>
            <count group_id="B2" value="263"/>
            <count group_id="B3" value="267"/>
            <count group_id="B4" value="793"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.7" spread="6.77"/>
                    <measurement group_id="B2" value="71.5" spread="5.89"/>
                    <measurement group_id="B3" value="71.7" spread="6.3"/>
                    <measurement group_id="B4" value="71.6" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="267"/>
                    <measurement group_id="B4" value="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula)</title>
        <description>The primary parameter of the study was the change (mL/min) from baseline in actual GFR (abbreviated MDRD formula using the patients’ actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>Per Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 3 mg Injection</title>
            <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 3 mg Infusion</title>
            <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Alendronate 70 mg Oral</title>
            <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula)</title>
          <description>The primary parameter of the study was the change (mL/min) from baseline in actual GFR (abbreviated MDRD formula using the patients’ actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
          <population>Per Protocol (PP) Population</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="18.25"/>
                    <measurement group_id="O2" value="71.5" spread="18.07"/>
                    <measurement group_id="O3" value="70.5" spread="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 9 months (n=233,232,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="7.14"/>
                    <measurement group_id="O2" value="-0.5" spread="7.86"/>
                    <measurement group_id="O3" value="-1.6" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula)</title>
        <description>Change (mL/min) from baseline in actual GFR (using Cockcroft-Gault [CG] formula) after 9 months (or 40 weeks) of treatment.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 3 mg Injection</title>
            <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 3 mg Infusion</title>
            <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Alendronate 70 mg Oral</title>
            <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula)</title>
          <description>Change (mL/min) from baseline in actual GFR (using Cockcroft-Gault [CG] formula) after 9 months (or 40 weeks) of treatment.</description>
          <population>PP Population</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="19.37"/>
                    <measurement group_id="O2" value="62.9" spread="18.22"/>
                    <measurement group_id="O3" value="62.0" spread="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 9 months (N=233,232,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="5.89"/>
                    <measurement group_id="O2" value="-1.0" spread="6.44"/>
                    <measurement group_id="O3" value="-1.9" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula)</title>
        <description>Change (mL/min) from baseline in actual GFR (abbreviated MDRD formula using the patient's actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 3 mg Injection</title>
            <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 3 mg Infusion</title>
            <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Alendronate 70 mg Oral</title>
            <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula)</title>
          <description>Change (mL/min) from baseline in actual GFR (abbreviated MDRD formula using the patient's actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
          <population>PP Population</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="18.25"/>
                    <measurement group_id="O2" value="71.5" spread="18.07"/>
                    <measurement group_id="O3" value="70.5" spread="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative Change at 9 month (n= 233, 232, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="10.01"/>
                    <measurement group_id="O2" value="-0.2" spread="10.73"/>
                    <measurement group_id="O3" value="-2.1" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in Actual GFR (Using CG Formula)</title>
        <description>Change (mL/min) from baseline in actual GFR (CG formula using the patient's actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 3 mg Injection</title>
            <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 3 mg Infusion</title>
            <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Alendronate 70 mg Oral</title>
            <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Actual GFR (Using CG Formula)</title>
          <description>Change (mL/min) from baseline in actual GFR (CG formula using the patient's actual body surface area) after 9 months (or 40 weeks) of treatment.</description>
          <population>PP Population</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="19.37"/>
                    <measurement group_id="O2" value="62.9" spread="18.22"/>
                    <measurement group_id="O3" value="62.0" spread="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative Change at 9 month (n=233,232,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="9.22"/>
                    <measurement group_id="O2" value="-1.3" spread="9.55"/>
                    <measurement group_id="O3" value="-2.8" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Mean Serum Creatinine.</title>
        <time_frame>Baseline and 9 months</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 3 mg Injection</title>
            <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 3 mg Infusion</title>
            <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Alendronate 70 mg Oral</title>
            <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Mean Serum Creatinine.</title>
          <population>PP Population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.17"/>
                    <measurement group_id="O2" value="0.8" spread="0.16"/>
                    <measurement group_id="O3" value="0.8" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 9 months (n=233,232,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.08"/>
                    <measurement group_id="O2" value="0.0" spread="0.08"/>
                    <measurement group_id="O3" value="0.0" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in Mean Serum Creatinine.</title>
        <time_frame>Baseline and 9 months</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 3 mg Injection</title>
            <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 3 mg Infusion</title>
            <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Alendronate 70 mg Oral</title>
            <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Mean Serum Creatinine.</title>
          <population>PP Population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.17"/>
                    <measurement group_id="O2" value="0.8" spread="0.16"/>
                    <measurement group_id="O3" value="0.8" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative Change at 9 months (n=233,232,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="8.87"/>
                    <measurement group_id="O2" value="0.8" spread="8.87"/>
                    <measurement group_id="O3" value="2.2" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Urine Albumin-to-Creatinine Ratio.</title>
        <time_frame>Baseline and 9 months</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 3 mg Injection</title>
            <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 3 mg Infusion</title>
            <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Alendronate 70 mg Oral</title>
            <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Urine Albumin-to-Creatinine Ratio.</title>
          <population>PP Population</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="17.30"/>
                    <measurement group_id="O2" value="14.1" spread="15.22"/>
                    <measurement group_id="O3" value="16.1" spread="19.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 9 months (n=233,232,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="18.54"/>
                    <measurement group_id="O2" value="0.5" spread="14.70"/>
                    <measurement group_id="O3" value="1.4" spread="22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio.</title>
        <description>The relative change from baseline in this case is positively skewed (while the absolute change is not) and the means tends to more positive values.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 3 mg Injection</title>
            <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 3 mg Infusion</title>
            <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Alendronate 70 mg Oral</title>
            <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio.</title>
          <description>The relative change from baseline in this case is positively skewed (while the absolute change is not) and the means tends to more positive values.</description>
          <population>PP Population</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="17.30"/>
                    <measurement group_id="O2" value="14.1" spread="15.22"/>
                    <measurement group_id="O3" value="16.1" spread="19.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative Change at 9 month (n=233,232,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="120.98"/>
                    <measurement group_id="O2" value="15.6" spread="62.32"/>
                    <measurement group_id="O3" value="28.3" spread="116.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs are considered to have occurred ‘On treatment’, defined as first dose and up 106 days after last dose if patient’s actual treatment is ibandronate, or up to 22 days after last dose if patient’s actual treatment is the alendronate.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ibandronate 3 mg Injection</title>
          <description>Ibandronate was administered as an intravenous (iv) injection (15 to 30 seconds) of 3 mg every 3 months.</description>
        </group>
        <group group_id="E2">
          <title>Ibandronate 3 mg Infusion</title>
          <description>Ibandronate was administered as an intravenous (iv) infusion (15 min) of 3 mg every 3 months.</description>
        </group>
        <group group_id="E3">
          <title>Alendronate 70 mg Oral</title>
          <description>Alendronate was administered as an oral tablet of 70 mg every week (Fosamax 70 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Conduction Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Multiple Drug Overdose Accidental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Breast Cancer Stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Ruptured Cerebral Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Senile Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Temporal Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glomerular Filtration Rate Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

